Affimed Prepares for the Cantor Global Healthcare Conference
Affimed N.V. (Nasdaq: AFMD), an innovative clinical-stage immuno-oncology company, is gearing up for a notable presence at the Cantor Global Healthcare Conference. This highly anticipated event will feature an engaging fireside chat with Affimed’s Chief Executive Officer, Shawn M. Leland, PharmD, RPh.
What to Anticipate from the Conference Presentation
The presentation is set for a dynamic discussion on a date that is sure to draw significant interest from the healthcare community. Affimed plans to present its vision for transforming cancer treatment and improving patient outcomes through groundbreaking therapies that harness the innate immune system's ability to combat cancer.
How to Access the Live Webcast
A live webcast of the presentation will be accessible on Affimed’s official website, allowing those who cannot attend in person to still gain valuable insights from this important information exchange. This initiative demonstrates Affimed’s dedication to transparency and engagement with its stakeholders.
Meet the Team Behind the Innovation
For attendees seeking more in-depth insights and discussions, Affimed’s management team will be available for one-on-one meetings throughout the conference. Participants are encouraged to connect through the contact channels provided by their Cantor Fitzgerald representatives or directly with Affimed.
About Affimed N.V.
Affimed N.V. is committed to restoring the body's natural capacity to fight cancer. By focusing on the innate immune system, the company’s innovative therapies aim to develop tumor-targeted treatments that effectively address a range of hematologic and solid tumors. Their innate cell engagers (ICE®) are a testament to their proprietary ROCK® platform, which creates custom-designed molecules optimized for maximum efficacy against cancer cells. As clinical trials advance, Affimed is excited about the potential breakthroughs in cancer treatment.
Dedication to Innovation and Patient Care
Based in Mannheim, Germany, Affimed's leadership team comprises experienced professionals from the biotechnology and pharmaceutical industries, united by a bold mission: to improve the lives of cancer patients around the world. As research and development continue to drive innovative treatments, the company remains focused on forging partnerships that enhance its capabilities and outreach.
Investor Relations Contact Information
For those interested in learning more about Affimed’s advancements, Alexander Fudukidis heads the Investor Relations team. He is available for direct contact via email or phone for inquiries regarding the company’s developments and opportunities.
Frequently Asked Questions
What is Affimed's main focus?
Affimed specializes in immuno-oncology, aiming to empower the innate immune system to combat various forms of cancer.
When will Affimed present at the conference?
The presentation is scheduled for the Cantor Global Healthcare Conference on the specified date, starting at 8:00 a.m. Eastern Time.
How can I access the webcast of the presentation?
You can watch the live webcast on Affimed’s official website during the event.
Who can I contact for more information about Affimed?
For inquiries, please reach out to Alexander Fudukidis, the Director of Investor Relations, via email or phone.
What are innate cell engagers (ICE®)?
ICE® are innovative therapies developed by Affimed that facilitate targeted tumor treatment by leveraging innate immune responses.
